Literature DB >> 9510214

Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases.

D P Purohit1, D P Perl, V Haroutunian, P Powchik, M Davidson, K L Davis.   

Abstract

BACKGROUND: Clinical studies suggest that severe cognitive impairment is common among elderly patients with schizophrenia who reside in long-stay psychiatric institutions; however, previous autopsy-based neuropathologic investigations have provided conflicting results about the occurrence of Alzheimer disease (AD) in elderly patients with schizophrenia. We report the results of a comprehensive neuropathologic study performed to identify AD and other dementing neurodegenerative diseases in elderly patients with schizophrenia.
METHODS: A neuropathologic examination was performed on 100 consecutive autopsy brain specimens of patients aged 52 to 101 years (mean, 76.5 years). A cognitive assessment of these cases was also done by employing the Clinical Dementia Rating Scale. For comparison, we included 47 patients with nonschizophrenic psychiatric disorders from the same psychiatric hospital and 50 age-matched control subjects.
RESULTS: Although 72% of the patients with schizophrenia showed cognitive impairment, AD was diagnosed in only 9% of the patients and other dementing diseases were diagnosed in only 4% of the patients. The degree of senile plaques or neurofibrillary tangles was not different in the group with schizophrenia compared with the age-matched controls or the group with nonschizophrenic psychiatric disorders. The higher Clinical Dementia Rating Scale scores lacked correlation with neuropathologic evidence of dementing disorders. In the 87 cases lacking a neuropathologic diagnosis of AD or other dementing disorders, the mean (+/-SD) Clinical Dementia Rating Scale score was 2.21 (+/-1.14), with 43 of the cases scoring 3 or higher (indicating severe, profound, or terminal cognitive impairment).
CONCLUSIONS: This study provides evidence that elderly patients with schizophrenia are not inordinately prone to the development of AD or to increased senile plaques or neurofibrillary tangle formation in the brain. Other dementing neurodegenerative disorders are also uncommon. The cognitive impairment in elderly patients with schizophrenia must, therefore, be related to some alternative mechanisms.

Entities:  

Mesh:

Year:  1998        PMID: 9510214     DOI: 10.1001/archpsyc.55.3.205

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  49 in total

1.  Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia.

Authors:  Pavel Katsel; William Byne; Panos Roussos; Weilun Tan; Larry Siever; Vahram Haroutunian
Journal:  Neuropsychopharmacology       Date:  2011-01-26       Impact factor: 7.853

2.  Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia.

Authors:  Patrick R Hof; Vahram Haroutunian; Christina Copland; Kenneth L Davis; Joseph D Buxbaum
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 3.  The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications.

Authors:  Paul J Harrison
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

Review 4.  Searching for neuropathology: gliosis in schizophrenia.

Authors:  Tatiana P Schnieder; Andrew J Dwork
Journal:  Biol Psychiatry       Date:  2010-10-30       Impact factor: 13.382

5.  Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia.

Authors:  Robert E McCullumsmith; Daya Gupta; Monica Beneyto; Emily Kreger; Vahram Haroutunian; Kenneth L Davis; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2007-01-12       Impact factor: 4.939

6.  Association of ApoE and LRP mRNA levels with dementia and AD neuropathology.

Authors:  Afia Akram; James Schmeidler; Pavel Katsel; Patrick R Hof; Vahram Haroutunian
Journal:  Neurobiol Aging       Date:  2011-06-15       Impact factor: 4.673

Review 7.  Psychiatric brain banking: three perspectives on current trends and future directions.

Authors:  Amy Deep-Soboslay; Francine M Benes; Vahram Haroutunian; Justin K Ellis; Joel E Kleinman; Thomas M Hyde
Journal:  Biol Psychiatry       Date:  2010-07-31       Impact factor: 13.382

8.  Gene expression elucidates functional impact of polygenic risk for schizophrenia.

Authors:  Menachem Fromer; Panos Roussos; Solveig K Sieberts; Jessica S Johnson; David H Kavanagh; Thanneer M Perumal; Douglas M Ruderfer; Edwin C Oh; Aaron Topol; Hardik R Shah; Lambertus L Klei; Robin Kramer; Dalila Pinto; Zeynep H Gümüş; A Ercument Cicek; Kristen K Dang; Andrew Browne; Cong Lu; Lu Xie; Ben Readhead; Eli A Stahl; Jianqiu Xiao; Mahsa Parvizi; Tymor Hamamsy; John F Fullard; Ying-Chih Wang; Milind C Mahajan; Jonathan M J Derry; Joel T Dudley; Scott E Hemby; Benjamin A Logsdon; Konrad Talbot; Towfique Raj; David A Bennett; Philip L De Jager; Jun Zhu; Bin Zhang; Patrick F Sullivan; Andrew Chess; Shaun M Purcell; Leslie A Shinobu; Lara M Mangravite; Hiroyoshi Toyoshiba; Raquel E Gur; Chang-Gyu Hahn; David A Lewis; Vahram Haroutunian; Mette A Peters; Barbara K Lipska; Joseph D Buxbaum; Eric E Schadt; Keisuke Hirai; Kathryn Roeder; Kristen J Brennand; Nicholas Katsanis; Enrico Domenici; Bernie Devlin; Pamela Sklar
Journal:  Nat Neurosci       Date:  2016-09-26       Impact factor: 24.884

Review 9.  Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

Authors:  Jun Ku Chung; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Danielle Uy; Philip Gerretsen; Fernando Caravaggio; M Mallar Chakravarty; Ariel Graff-Guerrero
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-29       Impact factor: 4.105

10.  Increased expression of RXRα in dementia: an early harbinger for the cholesterol dyshomeostasis?

Authors:  Afia Akram; James Schmeidler; Pavel Katsel; Patrick R Hof; Vahram Haroutunian
Journal:  Mol Neurodegener       Date:  2010-09-15       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.